Hemstreet G P, Dawson J R, Seigler H F
Cancer Res. 1978 May;38(5):1447-56.
Peripheral blood lymphocytes from 15 patients with hypernephroma were stimulated with partially purified tumor plasma membranes to incorporate [3H]thymidine. Kidney tumor and normal kidney membranes were adjusted to antigenic equivalence as determined by their ability to inhibit in the HLA 51Cr microcytotoxicity assay. Membranes from control "normal" kidney adjacent to the tumor stimulated less than did the tumor. Six of eight patients responded to autologous tumor (p less than 0.05). One patient responded to allogeneic tumor of the same histological type. The importance of statistical analyses of tumor membrane lymphocyte stimulation data is discussed in relation to the assay system. Sequential studies suggest that this assay may be useful as a guideline for the monitoring of current therapeutic regimens and future immunotherapy. The results of this assay are discussed in relation to other in vitro tumor lymphocyte stimulation assays. The limitations of this assay appear to be two: (a) it can be used only in large tumor systems where there is adequate tissue for analysis and controls; (b) it may detect nontumorous antigens or nonspecific stimulators in allogeneic studies. Further studies are needed to correlate the blastogenic response with the patient's prognosis.
用部分纯化的肿瘤质膜刺激15例肾细胞癌患者的外周血淋巴细胞,使其掺入[3H]胸腺嘧啶核苷。通过在HLA 51Cr微量细胞毒性试验中抑制的能力,将肾肿瘤和正常肾膜调整至抗原等价。肿瘤旁对照“正常”肾的膜刺激作用小于肿瘤膜。8例患者中有6例对自体肿瘤有反应(p<0.05)。1例患者对相同组织学类型的同种异体肿瘤有反应。结合检测系统讨论了肿瘤膜淋巴细胞刺激数据统计分析的重要性。序贯研究表明,该检测方法可能有助于监测当前的治疗方案和未来的免疫治疗。结合其他体外肿瘤淋巴细胞刺激试验讨论了该检测结果。该检测方法的局限性似乎有两个:(a)它仅适用于有足够组织进行分析和对照的大型肿瘤系统;(b)在同种异体研究中,它可能检测到非肿瘤抗原或非特异性刺激物。需要进一步研究以将增殖反应与患者的预后相关联。